Epigen Biosciences

Epigen Biosciences is a preclinical biotech firm leveraging a multi-target approach to develop novel therapeutics for fibrotic and neurodegenerative diseases with high unmet need. Its pipeline is built on three core platforms: an LPA1 receptor antagonist for fibrosis, sigma-1 receptor ligands for neurodegeneration, and a p70 S6 kinase inhibitor for Fragile X Syndrome. The company employs innovative research models, including cerebral organoids, and collaborates with academic institutions like UCSD to advance its programs toward clinical development.

Rational design of selective small-molecule therapeutics targeting specific receptors/pathways (LPA1R, Sigma-1R, p70 S6 Kinase, α7 nAChR PAMs). Utilizes novel models like cerebral organoids for drug discovery.

In fibrosis, Epigen's LPA1 antagonist will compete with other anti-fibrotic approaches from companies like Bristol Myers Squibb, Galapagos, and others. In Alzheimer's, the S1R ligand enters a crowded field dominated by amyloid- and tau-targeting therapies. For Fragile X, the p70 S6K inhibitor represents a novel, mechanism-specific approach in a space with very few disease-modifying candidates.